Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572041 | 1.00 | TDP1 (0.39) | TDP1ALDH1A1PPARGPPARDPPARA | |
| Monoethanolamine SCHEMBL28484082 | 0.89 | CNR1 (0.33) | TDP1ALDH1A1CNR1 | |
| SCHEMBL4400514 | 0.88 | — | — | |
| SCHEMBL4582063 | 0.88 | — | — | |
| SCHEMBL8459286 | 0.87 | SOAT1 (0.41) | TDP1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL8459292 | 0.87 | SOAT1 (0.41) | TDP1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL4553010 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL4553011 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL9389879 | 0.84 | TDP1 (0.41) | TDP1ALDH1A1PPARGPPARDPPARA | |
| SCHEMBL9389884 | 0.84 | TDP1 (0.41) | TDP1ALDH1A1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271570-A | Preparation method of organic phosphine-terminated non-conjugated oxygen-enriched fluorescent polymer, and product and application thereof | 浙江大学 | 2024-07-02 | — | — | CN | claimed |
| CN-115197174-B | Binaphthol-based epoxy resin monomer, preparation method thereof and application thereof in preparation of all-bio-based epoxy resin | 南京工业大学 | 2023-09-19 | — | — | CN | claimed |
| CN-115197174-A | Binaphthol-based epoxy resin monomer, preparation method thereof and application thereof in preparation of all-bio-based epoxy resin | 南京工业大学 | 2022-10-18 | — | — | CN | claimed |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-15 | — | — | US | claimed |
| EP-2871952-A1 | INSECTICIDAL FORMULATIONS OF MICROCAPSULES | Endura S.p.a. (IT) | 2015-05-20 | — | — | EP | claimed |
| WO-2014009269-A1 | INSECTICIDAL FORMULATIONS OF MICROCAPSULES | ENDURA S.P.A (IT) | 2014-01-16 | — | — | WO | claimed |
| WO-2013163454-A2 | PSYLLID ATTRACTANTS AND THEIR USES | INSCENT, INC. (US) | 2013-10-31 | — | — | WO | claimed |
| EP-2601187-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | Conrig Pharma ApS (DK) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | claimed |
| EP-1284653-B1 | INFRARED THERMOGRAPHY AND TREATMENT OF SEXUAL DYSFUNCTIONS | NITROMED INC (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | claimed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| US-12195587-B2 | Synthesis of a biocompatible, biodegradable, and tunable shape memory polymer triggered at body temperature | SHAPE MEMORY POLYMERS INC (CA) | 2025-01-14 | — | — | US | disclosed |
| US-12036078-B2 | Oral products and methods for producing the same | PolySpectra, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20020198426-A1 | Selective ring-opening cross-metathesis of cycloolefins | CYMETECH, LLC | 2002-12-26 | — | — | US | disclosed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198426-A1 | Selective ring-opening cross-metathesis of cycloolefins | KMO, COASY, OXER1 | TDP1 4274/4885ALDH1A1 2828/4885PPARG 4630/4885 |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | CLCN2, ODC1, KCNN4 | TDP1 3682/4885ALDH1A1 685/4885PPARG 3653/4885 |
| US-12036078-B2 | Oral products and methods for producing the same | CROCC, RPAP1, RUVBL1 | TDP1 1727/4885ALDH1A1 4171/4885PPARG 970/4885 |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NOS1, NOS2, NOS3 | TDP1 580/4885ALDH1A1 507/4885PPARG 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.